Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler, Hans Thorhauge Dam, R Gniadecki, Knud Kragballe, G B E Jemec, T Agner

25 Citationer (Scopus)

Abstract

Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).
OriginalsprogEngelsk
TidsskriftJournal of the European Academy of Dermatology and Venereology : JEADV
Vol/bind24
Udgave nummer7
Sider (fra-til)837-9
Antal sider3
DOI
StatusUdgivet - 1 jul. 2010

Fingeraftryk

Dyk ned i forskningsemnerne om 'Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases'. Sammen danner de et unikt fingeraftryk.

Citationsformater